Results 1 to 10 of about 436,513 (228)

Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis. [PDF]

open access: goldSci Rep
Uveitis is characterised by breakdown of the blood-retinal barrier (BRB), allowing infiltration of immune cells that mediate intraocular inflammation, which can lead to irreversible damage of the neuroretina and the loss of sight.
Quinn J   +10 more
europepmc   +3 more sources

SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis

open access: yesFrontiers in Immunology, 2023
Autoimmune diseases arise from atypical immune responses that attack self-tissue epitopes, and their development is intricately connected to the disruption of the JAK-STAT signaling pathway, where SOCS proteins play crucial roles.
Rahul Pandey   +3 more
doaj   +2 more sources

Altered Metabolic Phenotype of Immune Cells in a Spontaneous Autoimmune Uveitis Model

open access: yesFrontiers in Immunology, 2021
As one of the leading causes of blindness worldwide, uveitis is an important disease. The exact pathogenesis of autoimmune uveitis is not entirely elucidated to date.
Claudia Barfüßer   +4 more
doaj   +2 more sources

Sleep loss potentiates Th17‐cell pathogenicity and promotes autoimmune uveitis

open access: yesClinical and Translational Medicine, 2023
Background Sleep loss (SL) is a health issue associated with the higher risk of autoimmune and inflammatory disorders. However, the connection between SL, the immune system, and autoimmune diseases remains unknown.
Xiuxing Liu   +14 more
doaj   +2 more sources

Inhibition of experimental autoimmune uveitis by intravitreal AAV-Equine-IL10 gene therapy

open access: greenPLoS ONE, 2022
Equine recurrent uveitis (ERU) is a spontaneous, painful, and vision threatening disease affecting up to 25% of equine populations worldwide. Current treatments of ERU are non-specific and have many side effects which limits them to short-term use.
Endia J. Santee   +9 more
openalex   +2 more sources

Long-term management of recurrent uveitis associated with autoimmune lymphoproliferative syndrome [PDF]

open access: goldJournal of Ophthalmic Inflammation and Infection
Background The purpose of this case report is to describe the long-term findings and management of recurrent uveitis in a patient with autoimmune lymphoproliferative syndrome (ALPS).
Timothy Kaftan   +9 more
doaj   +2 more sources

Combined Therapy of Experimental Autoimmune Uveitis by a Dual-Drug Nanocomposite Formulation with Berberine and Dexamethasone

open access: yesInternational Journal of Nanomedicine, 2023
Chang Huang,1,2,* Zhutian Zhang,1,2,* Jifeng Gu,3,* Dan Li,1,2 Shunxiang Gao,1,2 Rong Zhang,1,2 Rong Shi,4 Jianguo Sun1,2 1Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai,
Huang C   +7 more
doaj   +2 more sources

Melanocortin receptor agonists suppress experimental autoimmune uveitis

open access: greenExperimental Eye Research, 2022
The melanocortin system plays an essential role in the regulation of immune activity. The anti-inflammatory microenvironment of the eye is dependent on the expression of the melanocortin-neuropeptide alpha-melanocyte stimulating hormone (α-MSH).
Tat Fong Ng   +2 more
openalex   +3 more sources

YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes

open access: yesAdvanced Science
Activated microglia in the retina are essential for the development of autoimmune uveitis. Yin‐Yang 1 (YY1) is an important transcription factor that participates in multiple inflammatory and immune‐mediated diseases.
Jiaxing Huang   +14 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy